The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - VBI Vaccines
Leadership - VBI Vaccines
Stock and Other Ownership Interests - VBI Vaccines
Travel, Accommodations, Expenses - VBI Vaccines
Evaluation of tumor responses and overall survival in patients with recurrent glioblastoma (GBM) from a phase IIa trial of a CMV vaccine immunotherapeutic candidate (VBI-1901).
 
Patrick Y. Wen
Consulting or Advisory Role - Agios; AstraZeneca; Bayer; Black Diamond Therapeutics; Blue Earth Diagnostics; Boston Pharmaceuticals; Celularity; Chimerix; Day One Biopharmaceuticals; ElevateBio; Imvax; Integral Health; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Novocure; Nuvation Bio; Prelude Therapeutics; QED Therapeutics; Sapience Therapeutics; Tocagen; Vascular Biogenics; VBI Vaccines; Voyager Therapeutics
Research Funding - Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Chimerix (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
David A. Reardon
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Omniox
 
Deborah Anne Forst
Stock and Other Ownership Interests - Lilly
 
Eudocia Quant Lee
Honoraria - Continuum (American Academy of Neurology); Medlink
Consulting or Advisory Role - Medscape
Patents, Royalties, Other Intellectual Property - Royalties from Wolter Kluwer for Up to Date, Inc
 
Brittany Haas
Employment - VBI Vaccines
Leadership - VBI Vaccines
Stock and Other Ownership Interests - VBI Vaccines
Travel, Accommodations, Expenses - VBI Vaccines
 
Teresa Daoud
Employment - VBI Vaccines
Leadership - VBI Vaccines
Stock and Other Ownership Interests - VBI Vaccines
Travel, Accommodations, Expenses - VBI Vaccines
 
Tamara Berthoud
Employment - VBI Vaccines
Leadership - VBI Vaccines
Stock and Other Ownership Interests - VBI Vaccines
Travel, Accommodations, Expenses - VBI Vaccines
 
Francisco Diaz-Mitoma
No Relationships to Disclose
 
David E Anderson
Employment - VBI Vaccines
Leadership - VBI Vaccines
Stock and Other Ownership Interests - VBI Vaccines
Patents, Royalties, Other Intellectual Property - As Chief Scientific Officer at VBI Vaccines, I am an inventor on much of the company's patent, including that of VBI-1901 (the subject of submitted abstract).
Travel, Accommodations, Expenses - VBI Vaccines
 
Andrew B. Lassman
Consulting or Advisory Role - Bayer; BioClinica; Chimerix; Elsevier; Karyopharm Therapeutics; Novocure; Orbus Therapeutics; Sapience Therapeutics; Vivacitas Oncology
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Bayer (Inst); BeiGene (Inst); BMS (Inst); Chimerix (Inst); Corden (Inst); DelMar Pharmaceuticals (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Millennium (Inst); NextSource (Inst); Novartis (Inst); Novocure (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); Semus (Inst); Servier (Inst); VBI Vaccines (Inst)
Travel, Accommodations, Expenses - Chimerix; Karyopharm Therapeutics; Novartis; Novocure; Orbus Therapeutics; Pfizer; QED Therapeutics; VBI Vaccines
 
Fabio Massaiti Iwamoto
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Gennao Bio; Guidepoint Global; Kiyatec; Massive Bio; Medtronic; Merck; MimiVax; Novocure; PPD; Regeneron; tocagen; Xcures
Speakers' Bureau - Prime Oncology
Research Funding - Bristol-Myers Squibb (Inst); Celldex (Inst); FORMA Therapeutics (Inst); Merck (Inst); Northwest Biotherapeutics (Inst); Novocure (Inst); Sapience Therapeutics (Inst); tocagen (Inst)
Travel, Accommodations, Expenses - Oncoceutics
(OPTIONAL) Uncompensated Relationships - Northwest Biotherapeutics